Navigation Links
Sirion Therapeutics Acquires Worldwide License to Develop New Treatment for Ocular Diseases
Date:2/20/2008

TAMPA, Fla., Feb. 20 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced that it has entered into an exclusive licensing agreement with Bridge Pharma, Inc. of Sarasota, FL for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge Pharma's proprietary anti- inflammatory agent norketotifen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )

"This agreement represents yet another significant milestone for Sirion. We are very excited about the medical and market potential of the norketotifen molecule," said Roger Vogel, MD, Chief Medical Officer of Sirion Therapeutics.

Under the terms of this licensing agreement, Sirion Therapeutics will have the rights to manufacture, sell and distribute norketotifen for ocular use either alone or in combination with other drugs. Norketotifen is a potent anti-inflammatory drug with additional antihistaminic activity that may have clinical utility in various ocular conditions.

"We hope to begin clinical trials with the new formulation of norketotifen in the first half of 2009," said Barry Butler, Chief Executive Officer of Sirion Therapeutics.

Dr. Gunnar Aberg, Chief Executive Officer of Bridge Pharma, said, "We are pleased to be working with Sirion Therapeutics, a company that has made impressive strides since its founding and is staffed with highly qualified individuals with many years of experience in developing and launching ophthalmic pharmaceuticals."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four compounds: difluprednate, a topical steroid for
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sirion Therapeutics Supports Ophthalmic Education
2. Ocera Therapeutics Closes $35.5 Million Series C Financing
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
4. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
5. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
6. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
7. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
8. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
11. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Incorporated (SPEX) -- an intellectual property development company committed to ... the United States Patent & Trademark Office (USPTO) issued a ... that is part of a standard essential family of patents. ... , Application number: US 13/728,867 , Publication date: Sep ... The listed inventors of the new patent, entitled ...
(Date:9/21/2014)... discovered how to produce ultra-thin "diamond nanothreads" that promise ... of today,s strongest nanotubes and polymers. A paper describing ... V. Badding, a professor of chemistry at Penn State ... issue of the journal Nature Materials . , ... intriguing because the threads we formed have a structure ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/20/2014)... Friesland, Netherlands (PRWEB) September 20, 2014 ... cell technologies to perform a groundbreaking surgery at the ... incident, the mare's superficial digital flexor tendon was ruptured ... this kind of injury is a death sentence for ... MediVet America stem cell treatments . This ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... 4 ARCA Discovery Inc., a privately held,biopharmaceutical ... other cardiovascular diseases, today announced Richard B.,Brewer, President ... 26th,Annual JPMorgan Healthcare Conference on Tuesday, January 8 ... Conference will be held January 7-10, 2008 at,the ...
... REYKJAVIK, Iceland, Jan. 4 deCODE genetics,(Nasdaq: DCGN ... webcast of deCODE,CEO Kari Stefansson,s presentation at the JPMorgan ... at 11:30 am PST / 7:30 pm GMT on,Thursday, ... California.,The webcast can be accessed through the Investors page ...
... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
Cached Biology Technology:ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008 2Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2
(Date:9/21/2014)... 2014The story of cowpea (black-eyed peas) is a fascinating ... problemseven more fascinating is the story of the scientist ... The Food Legume of the 21st Century to serve ... use. The book was recently published by the Crop ... of Tropical Agriculture (IITA). , Singh has devoted his ...
(Date:9/21/2014)... recent years, new strains of bacteria have emerged that ... superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ... least 23,000. Despite the urgent need for new treatments, ... in the past decade. , MIT engineers have now ... a gene-editing system that can disable any target gene, ...
(Date:9/21/2014)... team of Stanford researchers has developed a protein therapy ... break away from original tumor sites, travel through the ... the body. , This process, known as metastasis, can ... "The majority of patients who succumb to cancer fall ... Cochran, an associate professor of bioengineering who describes a ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... Md. -- Later this week, the American Society of Plant ... plant science to chart the future of the field. The ... the broad plant science research community in a process that ... science research over the next decade. The summit will ...
... A University of Alberta research team has turned their ... and hopes to expand its use. U ... students produced a 3-D imaging system called Virtual Reflected-Light ... a light source, a platform that moves the objects ...
... woodland creatures, including woodlice, millipedes and worms, can help ... according to new research from Cardiff University. Huge ... compete with each other for space and resources and, ... woodland floor have the potential to govern the outcome ...
Cached Biology News:ASPB convenes leaders to chart future of plant science research 2Peacekeeping creatures help maintain woodland diversity 2
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Request Info...
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Biology Products: